전문 번역가, 번역 회사, 웹 페이지 및 자유롭게 사용할 수 있는 번역 저장소 등을 활용합니다.
Παηδηά θαη έθεβνη
children and adolescents
마지막 업데이트: 2017-04-26
사용 빈도: 1
품질:
Παηδηά (3-<9 εηώλ)
children (3-<9 years)
마지막 업데이트: 2017-04-26
사용 빈도: 1
품질:
경고: 보이지 않는 HTML 형식이 포함되어 있습니다
Όιεο νη αλεπηζύκεηεο ελέξγεηεο αμηνινγήζεθαλ ζε 1940 παηδηά.
all adverse reactions were evaluated in 1940 children.
마지막 업데이트: 2017-04-26
사용 빈도: 1
품질:
Ζ ρξήζε ηνπ sprimeo ζε παηδηά θαη εθήβνπο δελ ζπληζηάηαη.
the use of sprimeo in children and adolescents is not recommended.
마지막 업데이트: 2017-04-26
사용 빈도: 1
품질:
Να θπιάζζεηαη ζε ζέζε ηελ νπνία δελ βιέπνπλ θαη δελ πξνζεγγίδνπλ ηα παηδηά
keep out of the reach and sight of children
마지막 업데이트: 2017-04-26
사용 빈도: 2
품질:
경고: 이 정렬은 잘못되었을 수 있습니다.
잘못된 경우 삭제해 주십시오.
Να θπιάζζεηαη ζε κέξε πνπ δελ ην θζάλνπλ θαη δελ ην βιέπνπλ ηα παηδηά.
keep out of the reach and sight of children.
마지막 업데이트: 2017-04-26
사용 빈도: 3
품질:
Αμηνιόγεζε ηεο αλνζνγνληθόηεηαο ζε παηδηά ειηθίαο από 9 έσο 12 κελώλ ηε ζηηγκή ηεο πξώηεο δόζεο
evaluation of immunogenicity in children from 9 to 12 months of age at the time of first dose
마지막 업데이트: 2017-04-26
사용 빈도: 1
품질:
Σν θάξκαθν απηφ πξέπεη λα θπιάζζεηαη ζε κέξε πνπ δελ ην βιέπνπλ θαη δελ ην θζάλνπλ ηα παηδηά.
keep this medicine out of the sight and reach of children.
마지막 업데이트: 2017-04-26
사용 빈도: 1
품질:
Ζ αζθάιεηα θαη ε απνηειεζκαηηθφηεηα ηνπ mirabegron ζε παηδηά ειηθίαο θάησ ησλ 18 εηψλ δελ έρνπλ αθφκα ηεθκεξησζεί.
the safety and efficacy of mirabegron in children below 18 years of age have not yet been established.
마지막 업데이트: 2017-04-26
사용 빈도: 1
품질:
Υξήζε ζηα παηδηά - Γελ ππάξρεη ζρεηηθή έλδεημε γηα ρξήζε ηνπ foscan ζε παηδηά ή εθήβνπο.
use in children - there is no relevant indication for use of foscan in children or adolescents.
마지막 업데이트: 2012-04-11
사용 빈도: 2
품질:
Έρεη αλαθεξζεί ΤΠΔ ζε παηδηά πνπ δελ είραλ ηζηνξηθό ινίκσμεο από θπζηθό ηό ηιαξάο αιιά πνπ είραλ ιάβεη εκβόιην ηιαξάο.
there have been reports of sspe in children who did not have a history of infection with wild-type measles but did receive measles vaccine.
마지막 업데이트: 2017-04-26
사용 빈도: 1
품질:
ε κία θιηληθή δνθηκή, 752 παηδηά έιαβαλ Μ-Μ-rvaxpro, είηε ελδνκπτθά ή ππνδόξηα.
in a clinical trial, 752 children received m-m-rvaxpro, either intramuscularly or subcutaneously.
마지막 업데이트: 2017-04-26
사용 빈도: 1
품질:
Ζ αζθάιεηα θαη ε απνηειεζκαηηθφηεηα ηνπ docetaxel teva pharma ζην ξηλνθαξπγγηθφ θαξθίλσκα ζε παηδηά ειηθίαο απφ 1 κελφο έσο θάησ ησλ 18 εηψλ δελ έρεη αθφκε εδξαησζεί.
the safety and efficacy of docetaxel teva pharma in nasopharyngeal carcinoma in children aged 1 month to less than 18 years have not yet been established.
마지막 업데이트: 2017-04-26
사용 빈도: 1
품질:
Πξέπεη λα ιακβάλεηαη ππόςε ζηηο έγθπεο γπλαίθεο ή γπλαίθεο πνπ ζειάδνπλ, γηα ηα παηδηά θαη ηηο νκάδεο πςεινύ θηλδύλνπ όπσο αζζελείο κε επαηηθή λόζν ή επηιεςία.
to be taken into account in pregnant or breast-feeding women, children and high-risk groups such as patients with liver disease or epilepsy.
마지막 업데이트: 2012-04-11
사용 빈도: 2
품질:
Μελ δίλεηε απηφ ην θάξκαθν ζε παηδηά θαη εθήβνπο ειηθίαο θάησ ησλ 18 εηψλ, δηφηη δελ έρεη ηεθκεξησζεί ε αζθάιεηα θαη ε απνηειεζκαηηθφηεηα ηνπ betmiga ζε απηή ηελ ειηθηαθή νκάδα.
do not give this medicine to children and adolescents under the age of 18 years because the safety and efficacy of betmiga in this age group has not been established.
마지막 업데이트: 2017-04-26
사용 빈도: 1
품질:
Πξνο ην παξόλ δελ ππάξρνπλ δηαζέζηκα ζηνηρεία γηα ηελ απνηειεζκαηηθόηεηα θαη αζθάιεηα από ηε ρξήζε ηνπ m-m-rvaxpro ζε παηδηά κηθξόηεξα ησλ 9 κελώλ.
no data on the efficacy and safety of m-m-rvaxpro for use in children below 9 months of age are currently available.
마지막 업데이트: 2017-04-26
사용 빈도: 1
품질:
Γεληθά ε θαξκαθνθηλεηηθή ηεο emtricitabine ζε βξέθε, παηδηά θαη εθήβνπο (ειηθίαο απφ 4 κελψλ έσο 18 εηψλ) είλαη παξφκνηα κε απηή ησλ ελειίθσλ.
in general, the pharmacokinetics of emtricitabine in infants, children and adolescents (aged 4 months up to 18 years) are similar to those seen in adults.
마지막 업데이트: 2017-04-26
사용 빈도: 1
품질:
Βξέθε, παηδηά θα έθεβνη βάξνπο 40 kg ή ιηγόηεξν: ε δφζε ηνπ emtriva 10 mg/ml πφζηκνπ δηαιχκαηνο ππνινγίδεηαη ζχκθσλα κε ην ζσκαηηθφ ζαο βάξνο.
infants, children and adolescents weighing 40 kg or less: the dose of emtriva 10 mg/ml oral solution is calculated according to your body weight.
마지막 업데이트: 2017-04-26
사용 빈도: 1
품질:
Σν riprazo hct δελ ζπληζηάηαη γηα ρξήζε ζε παηδηά θαη εθήβνπο θάησ ησλ 18 εηψλ ιφγσ έιιεηςεο ζηνηρείσλ γηα ηελ αζθάιεηα θαη ηελ απνηειεζκαηηθφηεηα (βι. παξάγξαθν 5.2).
riprazo hct is not recommended for use in children and adolescents below age 18 due to a lack of data on safety and efficacy (see section 5.2).
마지막 업데이트: 2017-04-26
사용 빈도: 1
품질:
Σν emtriva δηαηίζεηαη επίζεο σο πφζηκν δηάιπκα 10 mg/ml γηα ρξήζε ζε βξέθε ειηθίαο 4 κελψλ θαη άλσ, ζε παηδηά θαη ζε αζζελείο, νη νπνίνη δελ είλαη ζε ζέζε λα θαηαπηνχλ θαςάθηα, ζθιεξά θαη αζζελείο κε λεθξηθή αλεπάξθεηα.
emtriva is also available as a 10 mg/ml oral solution for use in infants aged 4 months and over, children and patients who are unable to swallow hard capsules and patients with renal insufficiency.
마지막 업데이트: 2017-04-26
사용 빈도: 1
품질: